Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Cancer of the ovary, fallopian tube, and peritoneum: 2025 update.

Cancer of the ovary, fallopian tube, and peritoneum: 2025 update. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics Renz, M., Friedlander, M., Berek, J. S. 2025; 171 Suppl 1: 6-35

Abstract

In 2014, FIGO's Committee for Gynecologic Oncology revised the staging of ovarian cancer, incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of these malignancies are high-grade serous carcinomas (HGSCs). Stage IC is now divided into three categories: IC1 (surgical spill), IC2 (capsule ruptured before surgery or tumor on ovarian or fallopian tube surface), and IC3 (malignant cells in the ascites or peritoneal washings). The updated staging includes a revision of Stage IIIC based on spread to the retroperitoneal lymph nodes alone without intraperitoneal dissemination. This category is now subdivided into IIIA1(i) (metastasis =10?mm in greatest dimension) and IIIA1(ii) (metastasis >10?mm in greatest dimension). Stage IIIA2 is now "microscopic extrapelvic peritoneal involvement with or without positive retroperitoneal lymph node" metastasis. This review summarizes the genetics, surgical management, chemotherapy, and targeted therapies for epithelial cancers, including the treatment of ovarian germ cell and stromal malignancies.

View details for DOI 10.1002/ijgo.70282

View details for PubMedID 40908761